TRAX

First Tracks Biotherapeutics Inc NASDAQ Listed Apr 20, 2026

Healthcare ·Biotechnology ·US

$16.15

-2.71% vs $16.60

Mkt Cap $563.5M

52w Low $14.72 11.8% of range 52w High $26.80

50d MA $19.45 200d MA $19.45

P/E (TTM) —

EV/EBITDA —

P/B —

Debt/Equity —

ROE —

P/FCF —

RSI (14) 49.00

ATR (14) $1.94

Beta 0.00

50d MA $19.45

200d MA $19.45

Avg Volume 503.9K

First Tracks Biotherapeutics, Inc. engages in the research and development of immunology therapeutics for autoimmune and inflammatory diseases. It focuses on clinical-stage programs for rosnilimab, ANB033 and ANB101. The company is headquartered in San Diego, CA.

SIC Code

2834

CIK (SEC)

2091349

Phone

212-373-3000

10770 WATERIDGE CIRCLE · San Diego, CA 92121 · US

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Jun 8	Wells Fargo	Initiates	Overweight	$30	—	—	—	—	—	—	—	—
May 4	Piper Sandler	Initiates	Overweight	$54	$22.38	$21.52	-3.8%	-8.2%	+3.1%	-4.4%	-12.0%	+9.7%
Apr 28	H.C. Wainwright	Initiates	Buy	$30	$18.10	$17.44	-3.6%	+10.8%	+17.9%	-1.6%	-3.8%	-8.2%
Apr 24	Leerink Partners	Initiates	Outperform	$46	$19.00	$20.20	+6.3%	-4.4%	-0.3%	+10.8%	+17.9%	-1.6%
Apr 24	Wedbush	Initiates	Outperform	$30	$19.00	$20.20	+6.3%	-4.4%	-0.3%	+10.8%	+17.9%	-1.6%
Apr 23	JP Morgan	Initiates	Overweight	$31	$18.87	$18.99	+0.6%	+0.7%	-4.4%	-0.3%	+10.8%	+17.9%
Apr 22	Barclays	Initiates	Overweight	$40	$17.00	$17.65	+3.8%	+11.0%	+0.7%	-4.4%	-0.3%	+10.8%
Apr 21	UBS	Initiates	Buy	$45	$18.60	$18.05	-3.0%	-8.6%	+11.0%	+0.7%	-4.4%	-0.3%

Data updated apr 27, 2026 5:29am · Source: financialmodelingprep.com